Longitudinal multimodal biomarker studies reveal that the continuum of Alzheimer's disease
(AD) includes a long latent phase, referred to as preclinical AD, which precedes the onset of …

Most neurodegenerative disorders are associated with aggregated protein deposits. In the
case of Alzheimer disease (AD), extracellular amyloid-β (Aβ) aggregates and intracellular …

β-Amyloid plaques and tau-containing neurofibrillary tangles are the two neuropathological
hallmarks of Alzheimer's disease (AD) and are thought to play crucial roles in a …

Background Similar to most chronic diseases, Alzheimer's disease (AD) develops slowly
from a preclinical phase into a fully expressed clinical syndrome. We aimed to use …

What can be expected in normal aging, and where does normal aging stop and pathological
neurodegeneration begin? With the slow progression of age-related dementias such as …

Background: The Australian Imaging, Biomarkers and Lifestyle (AIBL) Study commenced in
2006 as a prospective study of 1,112 individuals (768 cognitively normal (CN), 133 with mild …

Alzheimer's disease (AD) is classically defined as a dual clinicopathological entity. The
recent advances in use of reliable biomarkers of AD that provide in-vivo evidence of the …

Context The ability to identify and quantify brain β-amyloid could increase the accuracy of a
clinical diagnosis of Alzheimer disease. Objective To determine if florbetapir F 18 positron …

The field of Alzheimer's disease (AD) research has grown exponentially over the past few
decades, especially since the isolation and identification of amyloid-β from postmortem …

Objective Assess Aβ deposition longitudinally and explore its relationship with cognition and
disease progression. Methods Clinical follow‐up was obtained 20±3 months after [11C] …